We're proud to be working with our customer, @argonne
, and delivering low latency and deterministic performance–both mission-critical to #fusionenergy reactor operations and stability.
RESEARCH
-
Groq et Argonne collaborent pour optimiser les réacteurs de fusion
By
–
-
Standardized Testing Fails to Differentiate Among Thousands of Students
By
–
There is a failure of standardized testing as it cannot distinguish between 10,000+ students. The SAT and GRE are too easy, especially the math sections.
-
AI Drug Discovery: Calibrating Expectations with Reality
By
–
#AI in drug discovery has incredible potential, but it remains hard and some of the hype may not be grounded in reality. Our CEO and founder @DaphneKoller spoke with @MaxGelman about why she believes the industry needs to calibrate people's expectations with what's possible. Endpoints News (@endpts) Despite a flood of companies entering the AI space, the field has little hard data to show for itself, at least as far as the public can see. And that begs the question: How much of the “AI revolution” is hype, and how much is grounded in reality? endpts.com/biopharma-has-hyp… — https://nitter.net/endpts/status/1496171266667073547#m
→ View original post on X — @daphnekoller, 2022-02-23 22:18 UTC
-
Announcing redun: Open-source workflow framework for data scientists
By
–
Excited to share redun with data scientists everywhere. We hope redun will help democratize data science at scale, and support robust, reproducible science. insitro (@insitro) We're excited to announce the open sourcing of redun, an expressive, efficient, and easy-to-use workflow framework designed to deal with complex, rapidly evolving scientific workflows spanning multiple data types. Read more here: insitro.medium.com/8b06b707a… — https://nitter.net/insitro/status/1456237571340652547#m
→ View original post on X — @daphnekoller, 2021-11-04 18:32 UTC
-
insitro Announces $400M Series C Financing for Drug Discovery
By
–
A major milestone in our journey, enabled by the many accomplishments of amazing insitrocytes and support of outstanding, long-term investors. We are excited to continue towards our goal of using #ML and data at scale to bring transformative #medicines to patients. https://t.co/XRGBVFoYMR
— Daphne Koller (@DaphneKoller) 16 mars 2021A major milestone in our journey, enabled by the many accomplishments of amazing insitrocytes and support of outstanding, long-term investors. We are excited to continue towards our goal of using #ML and data at scale to bring transformative #medicines to patients. insitro (@insitro) We're thrilled to announce our $400M Series C financing, which will greatly enable us to continue advancing our vision to reshape the discovery and development of transformative medicines by leveraging #machinelearning and biology and chemistry at scale. bwnews.pr/3eL7G7v — https://nitter.net/insitro/status/1371416831840374789#m
→ View original post on X — @daphnekoller, 2021-03-16 01:54 UTC
-
Daphne Koller featured in Forbes article on ML for drug discovery
By
–
Thanks @_RobToews for including me in your @Forbes article and letting me talk about our work about our work at @insitro on using #ML for drug discovery. Honored to be included with a group of such amazing women scientists. bit.ly/3qU1DBa
→ View original post on X — @daphnekoller, 2020-12-13 23:45 UTC
-
Behind the Tech 2020 wrap-up with diverse technology leaders
By
–
Christina Warren (@Film_Girl), and I wrap up 2020’s #BehindTheTech with a few of the fascinating guests we've had on the podcast this year. Hear from leaders in a wide range of tech sectors – from #ArtificialIntelligence to synthetic biology. msft.it/6008pRIar
→ View original post on X — @daphnekoller, 2020-12-09 17:17 UTC